CN114042116A - Natural coconut fat solvent for resisting human immunodeficiency virus, preparation method and application - Google Patents
Natural coconut fat solvent for resisting human immunodeficiency virus, preparation method and application Download PDFInfo
- Publication number
- CN114042116A CN114042116A CN202111340130.6A CN202111340130A CN114042116A CN 114042116 A CN114042116 A CN 114042116A CN 202111340130 A CN202111340130 A CN 202111340130A CN 114042116 A CN114042116 A CN 114042116A
- Authority
- CN
- China
- Prior art keywords
- product
- acid
- caprylic
- coconut oil
- fractionation product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/005—Ingredients of undetermined constitution or reaction products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/408—Virucides, spermicides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Alternative & Traditional Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a natural coconut fat solvent resisting human immunodeficiency virus and a preparation method and application thereof. The natural coconut fat solvent for resisting human immunodeficiency virus is used for coating sanitary protective articles for vagina or anus of human body, and can also be coated on condoms or adult articles for use. The natural coconut fat solvent has the function of resisting HIV virus, wherein the activity rate of resisting HIV-1 virus can reach 99.26%, and the natural coconut fat solvent has the function of preventing and treating AIDS.
Description
Technical Field
The invention relates to a natural coconut fat solvent for resisting Human Immunodeficiency Virus (HIV), a preparation method and application thereof. Belongs to the technical field of medical health and health adult products.
Background
AIDS is caused by HIV infection, HIV virus attacks human immune cells CD4-T, which is an infectious disease seriously threatening human health, and hundreds of AIDS vaccine clinical tests are carried out globally since HIV is confirmed to be an AIDS pathogen in 1982, and the results show that all vaccines can not prevent AIDS. HIV has two types, namely HIV-1 and HIV-2, the HIV-1 is popular globally, the HIV-2 is popular in Western Africa and Western Europe, the HIV-1 is easy to mutate, the mutation rate of the HIV-1 is similar to that of influenza viruses, because the entrance of early replication and proliferation of the HIV viruses occurs in the vagina or anus, the pH of lubricant methyl silicone oil and hyaluronic acid on the traditional condom is 5-7, a large amount of beneficial lactic acid bacteria (the beneficial lactic acid bacteria are suitable for the growth environment with pH of 4-4.5), the pH of healthy vagina is destroyed in the acid-base balance environment with pH of 3.8-4.5, the pH of the vagina is increased by more than 5 to cause ecological acid-base imbalance, the pH of 5-9 is suitable for replication and proliferation of the HIV viruses, and the failure rate of using the traditional condom for preventing the HIV viruses is about 15-30%. Thus, a key to the prevention of aids is to protect the vagina or anus from the initial sites of HIV viral contact.
Disclosure of Invention
The invention aims to solve the technical problem of the prior art and provides a natural coconut fat solvent for resisting human immunodeficiency virus, a preparation method and application thereof aiming at the defects of personal protection in the prior art, the natural coconut fat solvent has the function of resisting HIV virus, wherein the activity rate of resisting HIV-1 virus can reach 99.26%, and the natural coconut fat solvent has the function of preventing and treating AIDS.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention firstly provides a preparation method of anti-human immunodeficiency virus natural coconut fat solvent, which comprises the following steps:
firstly, fractionating and extracting a lauric acid fractionation product, a caprylic acid fractionation product and a capric acid fractionation product from coconut oil, then synthesizing the caprylic acid fractionation product and the capric acid fractionation product into caprylic-capric acid glyceride oil solution through a polarization reaction, adding the coconut oil and the lauric acid fractionation product into the caprylic-capric acid glyceride oil solution, and then obtaining the natural coconut oil solvent through a catalytic reaction.
In the technical scheme, the coconut oil is a food-grade pure natural coconut essence extract, no chemical agent is added, and the collection of the coconut for obtaining the coconut oil is limited in a place with a north latitude of 19 degrees and an east longitude of 110 degrees and collected in winter; the main physical and chemical indexes of the coconut oil are as follows: acid value of 0.31mg/g, insoluble impurities of 0.01g/100g, saponification value of 253mg/g, peroxide value of 0.0021g/100g, water content and volatile matter of 0.02g/100g, lead can not be detected, total arsenic can not be detected, and aflatoxin can not be detected.
In the technical scheme, the lauric acid fractionation product, the caprylic acid fractionation product and the capric acid fractionation product are extracted from coconut oil by fractionation, and the operation method comprises the following steps: fractionating coconut oil at 60 deg.C under 0.8Mpa for 90min to obtain lauric acid product, fractionating at 50 deg.C under 0.7Mpa for 50min to obtain caprylic acid product, and fractionating at 40 deg.C under 0.6Mpa for 40min to obtain capric acid product.
In the above technical solution, the lauric acid fractionation product, the caprylic acid fractionation product, and the capric acid fractionation product extracted by fractionation from coconut oil, wherein: 49-52% of lauric acid, 7.5-7.7% of caprylic acid and 8.2-8.4% of capric acid.
In the technical scheme, the caprylic acid fractionation product and the capric acid fractionation product are synthesized into caprylic-capric glyceride oil solution through a polarization reaction, and the operation method comprises the following steps: mixing the components in a weight ratio of 1: 1, reacting the caprylic acid fractionation product and the capric acid fractionation product at 42 ℃ and 0.6Mpa for 60min to synthesize the caprylic-capric glyceride oil solution.
In the technical scheme, the weight ratio of the caprylic/capric glyceride oil solution to the lauric acid fractionation product to the coconut oil is 1: 3: 5, mixing the three, stirring for 40min at the speed of 100r/min at the temperature of 42 ℃ until the natural coconut fat solvent for resisting the human immunodeficiency virus.
The invention also provides a natural coconut fat solvent for resisting human immunodeficiency virus, which is prepared by the preparation method and has the following types: and (4) X135.
The invention also provides an application of the natural coconut fat solvent for resisting the human immunodeficiency virus in the aspect of being directly coated on the vagina or anus of a human body as a sanitary protective product.
The invention also provides the application of the natural coconut fat solvent for resisting the human immunodeficiency virus in preparing condoms or adult products entering the vagina or anus of a human body;
in the technical scheme, when the condom or the adult product entering the vagina or the anus of a human body is prepared, the anti-human immunodeficiency virus natural coconut fat solvent is coated on the outer surface of the condom or the outer surface of the adult product.
The principle of the anti-HIV virus of the anti-human immunodeficiency virus natural coconut fat solvent of the invention is as follows:
the outer layer of the HIV virus is a lipoprotein envelope, two glycoproteins, namely surface protein (gp120) and mosaic protein (gp41), are arranged on the envelope, the gp120 is a spike, and the gp41 is transmembrane protein, is not acid-resistant, is stable within the pH range of 5-9, and can be inactivated below pH 5. The natural coconut fat solvent with the pH value of 4-4.2 can dissolve HIV virus surface antibodies gp120, gp41 and envelope to enable the HIV virus surface antibodies gp120, gp41 and envelope to lose adsorption force and be inactivated, the natural coconut fat solvent is coated and expressed on vaginal mucosa and spreads under the body temperature effect to form an acid barrier with the pH value of 4-4.2, the space occupying protection effect is achieved, the HIV virus is prevented from adsorbing the mucosa to cause infection, the vaginal microecological pH is helped to be 3.8-4.5, most advantages of beneficial lactic acid bacteria are maintained, and the beneficial lactic acid bacteria can release H2O2Antagonize HIV viral replication; the natural coconut fat solvent is coated and expressed on anorectal mucosa, and is spread under the body temperature effect to form an acid barrier with the pH value of 4-4.2, so that the space occupying protection effect is achieved, and HIV virus is prevented from adsorbing the mucosa to cause infection; when the natural coconut fat solvent is coated on condoms or adult products and enters the vagina or anus, the natural coconut fat solvent is adsorbed by mucous membranes to form an acid barrier with the pH value of 4-4.2, and HIV virus in a habitat with the pH value of less than 5 cannot be replicated and inactivated.
The present invention has the following advantageous effects
The natural coconut fat solvent for resisting human immunodeficiency virus can dissolve and inactivate surface antibodies gp120, gp41 and envelope of HIV virus, so that the surface antibodies lose adsorption capacity and lose infectivity, wherein the activity rate of resisting HIV-1 virus can reach 99.26%, and the natural coconut fat solvent has the effect of preventing and treating AIDS.
Detailed Description
The following detailed description of the embodiments of the present invention is provided, but the present invention is not limited to the following descriptions:
the invention will now be illustrated with reference to specific examples:
example 1:
a natural coconut fat solvent for resisting human immunodeficiency virus is prepared by the following steps:
(1) fractionating coconut oil at 60 deg.C under 0.8Mpa for 90min to obtain lauric acid product, fractionating at 50 deg.C under 0.7Mpa for 50min to obtain caprylic acid product, and fractionating at 40 deg.C under 0.6Mpa for 40min to obtain capric acid product. Wherein: lauric acid content of 51%, caprylic acid content of 7.6% and capric acid content of 8.3%.
(2) Mixing the components in a weight ratio of 1: 1, reacting the caprylic acid fractionation product and the capric acid fractionation product at 42 ℃ and 0.6Mpa for 60min to synthesize caprylic/capric acid glyceride oil solution.
(3) Mixing the components in a weight ratio of 1: 3: 5, mixing the caprylic capric acid glyceride, lauric acid fractionation product and coconut oil, and stirring at 42 deg.C at 100r/min for 40min to obtain the natural coconut fat solvent (type: X135) for resisting human immunodeficiency virus.
In the embodiment, the coconut oil is a food-grade pure natural coconut essence extract, no chemical agent is added, and the collection of the coconut oil is limited in a place with a north latitude of 19 degrees and an east longitude of 110 degrees and collected in winter; the main physical and chemical indexes of the coconut oil are as follows: acid value of 0.31mg/g, insoluble impurities of 0.01g/100g, saponification value of 253mg/g, peroxide value of 0.0021g/100g, water content and volatile matter of 0.02g/100g, lead can not be detected, total arsenic can not be detected, and aflatoxin can not be detected.
And (3) detection report:
the natural coconut fat solvent for resisting the human immunodeficiency virus obtained in the embodiment 1 of the invention is sent to Shanghai micro-spectrum chemical engineering service company Limited for detection, and the name of the sample to be detected is as follows: the natural coconut fat solvent has the following types: x135, the detection items are: anti-HIV-1 activity, detection standard: ISO18184:2019, detection instrument is: the biological safety cabinet has the detection results shown in table 1: table 1: anti-HIV-1 activity of natural coconut fat solvent for resisting human immunodeficiency virus
Remarking:
(1) the ambient temperature in the whole detection process is 28.5 ℃.
(2) The dissolution temperature of the coconut butter solvent was tested after 36 deg.C transformation from solid to liquid according to the customer's requirements.
As shown in Table 1, the anti-HIV natural coconut fat solvent provided by the invention has the function of resisting HIV virus through the verification of a third party detection institution.
The above examples are only for illustrating the technical concept and features of the present invention, and are not intended to limit the scope of the present invention. All equivalent changes or modifications made according to the spirit of the present invention should be covered within the protection scope of the present invention.
Claims (10)
1. A preparation method of natural coconut fat solvent for resisting human immunodeficiency virus is characterized by comprising the following steps:
firstly, fractionating and extracting a lauric acid fractionation product, a caprylic acid fractionation product and a capric acid fractionation product from coconut oil, then synthesizing the caprylic acid fractionation product and the capric acid fractionation product into caprylic-capric acid glyceride oil solution through a polarization reaction, adding the coconut oil and the lauric acid fractionation product into the caprylic-capric acid glyceride oil solution, and then obtaining the natural coconut oil solvent through a catalytic reaction.
2. The method for preparing the coconut oil as claimed in claim 1, wherein the coconut oil is a food grade pure natural coconut essence extract, no chemical agent is added, the collection of coconut for obtaining the coconut oil is limited to the place of northeast longitude at 19 degrees north latitude at 110 degrees and collected in winter; the main physical and chemical indexes of the coconut oil are as follows: acid value of 0.31mg/g, insoluble impurities of 0.01g/100g, saponification value of 253mg/g, peroxide value of 0.0021g/100g, water content and volatile matter of 0.02g/100g, lead can not be detected, total arsenic can not be detected, and aflatoxin can not be detected.
3. The preparation method according to claim 1, characterized in that the fractionation and extraction of lauric acid fractionation product, caprylic acid fractionation product and capric acid fractionation product from coconut oil is carried out by the following operation methods: fractionating coconut oil at 60 deg.C under 0.8Mpa for 90min to obtain lauric acid product, fractionating at 50 deg.C under 0.7Mpa for 50min to obtain caprylic acid product, and fractionating at 40 deg.C under 0.6Mpa for 40min to obtain capric acid product.
4. The method according to claim 1, wherein the lauric acid fractionation product, the caprylic acid fractionation product, and the capric acid fractionation product are fractionated and extracted from coconut oil, wherein: 49-52% of lauric acid, 7.5-7.7% of caprylic acid and 8.2-8.4% of capric acid.
5. The preparation method of claim 1, wherein the caprylic acid fractionation product and the capric acid fractionation product are synthesized into caprylic-capric glyceride oil solution by polarization reaction, and the operation method comprises the following steps: mixing the components in a weight ratio of 1: 1, reacting the caprylic acid fractionation product and the capric acid fractionation product at 42 ℃ and 0.6Mpa for 60min to synthesize the caprylic-capric glyceride oil solution.
6. The preparation method according to claim 1, wherein the weight ratio of the caprylic/capric glyceride oil solution to the lauric acid fractionated product to the coconut oil is 1: 3: 5, mixing the three, stirring for 40min at the speed of 100r/min at the temperature of 42 ℃ until the natural coconut fat solvent for resisting the human immunodeficiency virus.
7. A natural coconut fat solvent for resisting human immunodeficiency virus prepared by the preparation method of any one of claims 1-6.
8. Use of the natural coconut oil solvent for anti-HIV according to claim 7 as a sanitary product to be applied directly to the vagina or anus of a human.
9. Use of the anti-HIV natural coconut fat solvent of claim 7 in the preparation of condoms or adult products for insertion into the vagina or anus of a human.
10. The use according to claim 9, wherein said anti-HIV natural coconut fat solvent is applied to the external surface of a condom or an adult article for its manufacture by entering the vagina or anus of a human.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111340130.6A CN114042116A (en) | 2021-11-12 | 2021-11-12 | Natural coconut fat solvent for resisting human immunodeficiency virus, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111340130.6A CN114042116A (en) | 2021-11-12 | 2021-11-12 | Natural coconut fat solvent for resisting human immunodeficiency virus, preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114042116A true CN114042116A (en) | 2022-02-15 |
Family
ID=80208815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111340130.6A Pending CN114042116A (en) | 2021-11-12 | 2021-11-12 | Natural coconut fat solvent for resisting human immunodeficiency virus, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114042116A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100021563A1 (en) * | 2008-07-24 | 2010-01-28 | Paul Levesque | Compositions comprising coconut oil and methods of use thereof |
| CN101938999A (en) * | 2007-12-04 | 2011-01-05 | 韦斯特盖特生物有限公司 | The antimicrobial compositions that comprises fatty acid and lactoprotein |
| CN113181084A (en) * | 2021-02-07 | 2021-07-30 | 北京健翔嘉业日用品有限责任公司 | Skin-care and bacteriostatic coconut fat solvent and preparation method and application thereof |
| CN113440641A (en) * | 2021-07-19 | 2021-09-28 | 北京健翔嘉业日用品有限责任公司 | Coconut fat solvent for resisting human papilloma virus and preparation method and application thereof |
-
2021
- 2021-11-12 CN CN202111340130.6A patent/CN114042116A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101938999A (en) * | 2007-12-04 | 2011-01-05 | 韦斯特盖特生物有限公司 | The antimicrobial compositions that comprises fatty acid and lactoprotein |
| US20100021563A1 (en) * | 2008-07-24 | 2010-01-28 | Paul Levesque | Compositions comprising coconut oil and methods of use thereof |
| CN113181084A (en) * | 2021-02-07 | 2021-07-30 | 北京健翔嘉业日用品有限责任公司 | Skin-care and bacteriostatic coconut fat solvent and preparation method and application thereof |
| CN113440641A (en) * | 2021-07-19 | 2021-09-28 | 北京健翔嘉业日用品有限责任公司 | Coconut fat solvent for resisting human papilloma virus and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 陈银基，等: "饱和脂肪酸分类与生理功能", 《中国油脂》 * |
| 黄艺珠，等: "中短链脂肪酸的联合使用", 《饲料工业》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Illanes-Álvarez et al. | Similarities and differences between HIV and SARS-CoV-2 | |
| CN111588732A (en) | Application of fucoidin in resisting novel coronavirus | |
| DE69936337T2 (en) | METHOD FOR DEVELOPING AN HIV VACCINE | |
| CN102245194B (en) | Composition for the prevention and treatment of viral infections | |
| CN114042116A (en) | Natural coconut fat solvent for resisting human immunodeficiency virus, preparation method and application | |
| US20120009286A1 (en) | Water-soluble antiviral product containing momordica balsamina, for the treatment and prevention of acquired immunodeficiency syndrome (aids) and the variants thereof | |
| Brown et al. | Respiratory virus antibodies in sera of persons living in isolated communities | |
| Begue et al. | Community-based assessment of safety and immunogenicity of the whole cell plus recombinant B subunit (WCrBS) oral cholera vaccine in Peru | |
| CN111773150A (en) | COVID-19 resistant hand-washing-free gel and preparation method thereof | |
| CN103736100B (en) | The microbicide acid anhydrides that prevention HIV spreads through sex intercourse modifies anti-SEVI polyclonal antibodies | |
| Moss et al. | Cross-clade immune responses after immunization with a whole-killed gp120-Depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 Immunogen, Remune™) in human immunodeficiency virus type-1 seropositive subjects | |
| JPH01120284A (en) | Incomplete particle of hiv and production thereof | |
| CA2529965A1 (en) | Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases | |
| CN113440641A (en) | Coconut fat solvent for resisting human papilloma virus and preparation method and application thereof | |
| Malcolm et al. | Vaginal microbicides for the prevention of HIV transmission | |
| Pak et al. | Human immunodeficiency virus (HIV) | |
| Oxford et al. | Challenges and strategies for AIDS vaccine development | |
| Zatla et al. | Re-emergence of monkeypox: a post-COVID-19 challenge | |
| CN104056268A (en) | New anti-human papilloma virus (HPV) and endometritis preparation | |
| CN103565970B (en) | A kind of Radix Sangusorbae extract for the treatment of acquired immune deficiency syndrome (AIDS) and preparation method thereof | |
| Rosahn et al. | Studies on the etiology of rabbit pox: Iv. tests on the relation of rabbit pox virus to other viruses by serum neutralization experiments | |
| Grandgeorge et al. | Inactivation of the human immunodeficiency viruses (HIV‐1 and HIV‐2) during the manufacturing of placental albumin and gammaglobulins | |
| Gust | Two antigenic specificities in the Australia antigen | |
| JPH04308531A (en) | Therapeutic agent for retrovirus infection containing sulfated beta-glucan having anti-aids virus activity | |
| CN101347492A (en) | Use of Trigonostemon xyphophylloides extract in preparing anti-AIDS medicament |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |